The Effect of Peritubal Infiltration With Bupivacaine Around Nephrostomy Tract on Postoperative Pain Control After Percutaneous Nephrolithotomy
Overview
- Phase
- Not Applicable
- Intervention
- Marcaine Injectable Product
- Conditions
- Renal Stone
- Sponsor
- Saddam Al Demour
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- visual analogue scale (VAS )
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The investigators aim to investigate the effect of peritubal local anesthetic infiltration on pain scores and analgesic consumption in patients who underwent percutaneous nephrolithotomy.
Detailed Description
The investigators aim to investigate the effect of peritubal local anesthetic on pain scores and analgesic consumption in patients who underwent percutaneous nephrolithotomy. Patients aged between 18 and 65 years with renal stone \>2 cm will be included in this study .The patients will be divided into two groups. In Group A , the drug will be infiltrated to the renal capsule, perinephric fat, muscles, subcutaneous tissue, and skin under fluoroscopy with 0.25 percent bupivacaine. This is a widely-used procedure by surgeons in the world. In Group B, no anesthetic will be infiltrated after the end of the procedure.
Investigators
Saddam Al Demour
Assistant Professor
University of Jordan
Eligibility Criteria
Inclusion Criteria
- •18-70 years of age
- •body mass index \<35,
- •renal stone size \>2.0 cm.
Exclusion Criteria
- •patients having supra-costal puncture.
- •excessive intraoperative bleeding.
- •renal stones requiring more than a single puncture.
- •surgical procedure extending more than 3 hours.
- •urinary tract infection.
- •severe cardiopulmonary disease.
- •abnormal renal function tests.
- •allergy to local anesthetics.
Arms & Interventions
study group :infiltration with 0.25% bupivacaine post-op
At the end of the procedure ( surgery), In the patients of the study group, the 23-gauge, 90mm spinal needle will inserted up to the renal capsule under fluoroscopic guidance along the nephrostomy tube at 6 and 12 o'clock positions (cranial and caudal); then 20 ml of 0.25% bupivacaine will infiltrated into the nephrostomy tract, while gradually withdrawing the needle from renal capsule to the skin thereby infiltrating the renal capsule, perinephric fat, muscles, subcutaneous tissue and skin
Intervention: Marcaine Injectable Product
Outcomes
Primary Outcomes
visual analogue scale (VAS )
Time Frame: 1, 4, 8, 12, 24, and 48 hours
Visual Analogue Scale (VAS), the patient is asked to describe the level of pain on a visual scale at rest at 1, 4, 8, 12, 24, and 48 hours
Dynamic Visual Analogue Scale (DVAS)
Time Frame: 1 hour, 4 hours, 8 hours, 12 hours, 24 hours, and 48 hours
Dynamic Visual Analogue Scale (DVAS), the patient is asked to describe the level of pain on a visual scale during breathing at 1, 4, 8, 12, 24, and 48 hours
Secondary Outcomes
- The time for the first opioid demand(48 hours)
- the number of opioid demands(48 hours)
- total opioid consumption(48 hours)